Clinical trial • Phase III • Other

Midazolam for Breech (podalic) or transverse fetal presentation (dystocic fetal presentation)

Phase III trial of Midazolam for Breech (podalic) or transverse fetal presentation (dystocic fetal presentation).

Overview

Trial Therapeutic Area
Other
Trial Disease
Breech (podalic) or transverse fetal presentation (dystocic fetal presentation)
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
20-08-2024
First CTIS Authorization Date
30-09-2024

Trial design

Randomised, open-label, groupe contrôle: 0.10 mg/kg midazolam, sublingual; groupe intervention: spinal (rachianesthesia) with 10 mg bupivacaine administered intrathecally using a 25 gauge needle in sitting position, aseptic technique.-controlled Phase III trial across 1 site in France.

Randomised
Yes
Open Label
Yes
Comparator
Groupe contrôle: 0.10 mg/kg midazolam, sublingual; Groupe intervention: spinal (rachianesthesia) with 10 mg bupivacaine administered intrathecally using a 25 gauge needle in sitting position, aseptic technique.
Target Sample Size
200

Eligibility

Recruits 200 Patients deprived of liberty or under legal protection (guardianship or curatorship) and patients unable to read or write are excluded; signed informed consent from the patient is required..

Vulnerable Population
Patients deprived of liberty or under legal protection (guardianship or curatorship) and patients unable to read or write are excluded; signed informed consent from the patient is required.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 18 years\n- Patient presenting with a dystocic (podalic or transverse) fetus at 36 weeks' gestation\n- Patient covered by a social insurance system\n- Signed informed consent"}

Exclusion criteria

  • {"criterion_text":"- Obstetrical contraindications : - Placenta previa ; - 3rd trimester metrorrhagia; - Suspicion of foetal anoxia; - Patient who has already had more than one caesarean section; - Twin pregnancies; - HIV+; - Anticoagulant treatment in progress\n- Anaesthetic contraindications : - Infection at the puncture site, generalised infection or severe septic state; - Intracranial hypertension; - Uncompensated heart failure; - Constitutive or acquired coagulation anomalies, including curative anticoagulant treatments; - Neuropathy with demyelination of nerve fibres in advanced stages or in the process of unstabilised recovery; - Syringomyelia\n- Patient deprived of liberty, under legal protection (guardianship or curatorship), unable to read or write."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Successful EMV once the procedure has been completed, i.e. a foetus in cephalic presentation.","definition_or_measurement_approach":"Defined as obtaining a foetus in cephalic presentation once the external cephalic version procedure has been completed."}

Secondary endpoints

  • {"endpoint_text":"- Events secondary to the procedure: caesarean section for permanent bradycardia, retroplacental haematoma, rupture of membranes","definition_or_measurement_approach":"Occurrence of procedure-related events including caesarean section for permanent fetal bradycardia, retroplacental haematoma, and rupture of membranes."}
  • {"endpoint_text":"- Events secondary to the anaesthetic: hypotension, bradycardia, desaturation, nausea/vomiting, number of punctures greater than 11 (failure of the first spinal puncture and need for one or more others)","definition_or_measurement_approach":"Occurrence of anaesthesia-related adverse events (hypotension, bradycardia, desaturation, nausea/vomiting) and count of punctures; number of punctures > 11 considered as failure of first spinal puncture."}
  • {"endpoint_text":"- The pain felt by the patient: assessed by VAS","definition_or_measurement_approach":"Patient-reported pain measured using the visual analogue scale (VAS/EVA)."}
  • {"endpoint_text":"- Final route of delivery","definition_or_measurement_approach":"Recorded final mode of delivery (vaginal/natural route or caesarean section)."}
  • {"endpoint_text":"- Presentation at delivery","definition_or_measurement_approach":"Recorded fetal presentation at delivery (cephalic or podalic)."}

Recruitment

Planned Sample Size
200
Recruitment Window Months
102
Consent Approach
Signed informed consent required from the patient. Subject information and informed consent forms are listed (L1_SIS_PATIENT, L1_ICF_PATIENT). No minors included; consent provided by the adult patient. Documentation available in French (translations present).

Geography

Total Number Of Sites
1
Total Number Of Participants
200

France

Latest Decision Or Authorization Date
30-09-2024
Number Of Sites
1
Number Of Participants
200

Sites

Site Name
Centre Hospitalier Universitaire Amiens Picardie
Department Name
service de gynécologie - obstétrique – orthogénie
Principal Investigator Name
Arthur FOULON
Principal Investigator Email
foulon.arthur@chu-amiens.fr
Contact Person Name
Arthur FOULON
Contact Person Email
foulon.arthur@chu-amiens.fr
Number Of Participants
200

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire Amiens Picardie
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
Midazolam 1 mg/ml Solution for Injection or Infusion
Active Substance
Midazolam
Modality
Small molecule
Routes Of Administration
sublingual (as per arm description); product form listed as solution for injection/infusion
Route
sublingual
Authorisation Status
Authorised (marketing authorisation PL 20075/0080)
Starting Dose
0.10 mg/kg (sublingual)
Maximum Dose
0.10 mg/kg
Investigational Product Name
BUPIVACAINE VIATRIS 20 mg/4 ml, solution injectable pour voie intra rachidienne en ampoule
Active Substance
Bupivacaine hydrochloride (anhydrous)
Modality
Small molecule
Routes Of Administration
intrathecal injection (rachianesthesia)
Route
intrathecal (injection)
Authorisation Status
Authorised (marketing authorisation 3400956311651)
Starting Dose
10 mg intrathecal (rachianesthesia)
Maximum Dose
10 mg

Related trials

Other published trials that may interest you.